Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: Mid-season analysis 2012/13

Eurosurveillance

Volumn 18, Issue 5, 2013, Pages

  McMenamin, J ^a   Andrews, N ^b   Robertson, C ^a,c,d   Fleming, D M ^e   Durnall, H ^e   von Wissmann, B ^a   Ellis, J ^b   Lackenby, A ^b   Cottrell, S ^f   Smyth, B ^g   Zambon, M ^b   Moore, C ^f   Watson, J M ^b   Pebody, R G ^b  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^e ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

^f PUBLIC HEALTH WALES   (United Kingdom)

^g PUBLIC HEALTH AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA B; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIMARY MEDICAL CARE; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT DISEASE; RESPIRATORY VIRUS; UNITED KINGDOM;

EID: 84873314142     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/ese.18.05.20393-en     Document Type: Article

References (16)

1. Pebody RG, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill. 2013;18(5):pii=20389. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20389
2. Health Protection Agency (HPA). Surveillance of influenza and other respiratory viruses in the UK: 2011-2012 report. London: HPA; Jun 2012. Available from:http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb_C/1317134576275
3. Jiménez-Jorge S, de Mateo S, Pozo F, Casas I, García Cenoz M, Castilla J et al. Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012. Euro Surveill. 2012;17(12):pii=20129. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20129
4. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. Geneva: WHO; 23 Feb 2012. Available from:http://www.who.int/influenza/vaccines/virus/recommendations/2012_13_north/en/index.html
5. Health Protection Agency (HPA). Weekly National Influenza Report. 17 January 2013-Week 3 report (up to week 2 data). London: HPA; 17 Jan 2013. Available from:http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317137745086
6. The Chief Medical Officer, the director of nursing and the chief pharmaceutical officer for England. The flu immunisation programme 2012/13. London: Department of Health; 3 May 2012. Available from:http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Professionalletters/DH_133888
7. Pebody RG, Andrews N, Fleming DM, McMenamin J, Cottrell S, Smyth B, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol. Infect. 2012:1-11.
8. Gunson R, Maclean A, Davies E, Bennett S, Miller R, Carman WF. Development of a multiplex real-time RT-PCR that allows universal detection of influenza A viruses and simultaneous typing of influenza A/H1N1/2009 virus. J Virol Methods. 2010;163(2):258-61.
9. Ellis J, Iturriza M, Allen R, Bermingham A, Brown K, Gray J, Brown D. Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Euro Surveill. 2009;14(22):pii=19230. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19230
10. To KK, Chan KH, Li IW, Tsang TY, Tse H, Chan JF, et al. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol. 2010;82(1):1-7.
11. Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009;48(4):389-96.
12. European Centre for Disease Prevention and Control (ECDC). Weekly influenza surveillance overview, Stockholm: ECDC; 18 Jan 2013. Available from:http://ecdc.europa.eu/en/publications/Publications/130118_SUR_Weekly_Influenza_Surveillance_Overview.pdf
13. Centers for Disease Control and Prevention (CDC). Early estimates of seasonal influenza vaccine effectiveness-United States, January 2013. MMWR Morb Mortal Wkly Rep. 2013;62:32-5. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6202a4.htm?s_cid=mm6202a4_w
14. Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter A, Mahmud SM, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5):pii=20394. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20394
15. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81-8.
16. European Medicines Agency (EMA). Amended EU recommendations for the seasonal influenza vaccine composition for the season 2012/2013. London: EMA; 19 Apr 2012. Available from:-http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/03/WC500124221.pdf